Navigation Links
Amgen's Denosumab and Eli Lilly's Forteo/Forsteo Will Drive Robust Annual Growth in the Osteoporosis Drug Market From 2013 to 2018
Date:6/1/2009

Denosumab and Forteo/Forsteo Will Each Achieve Blockbuster Status in 2018, According to a New Report from Decision Resources

WALTHAM, Mass., June 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen's novel agent denosumab and Eli Lilly's parathyroid hormone (PTH) analogue Forteo/Forsteo (teriparatide) will drive robust 4.3 percent annual growth in the osteoporosis drug market from 2013 to 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Osteoporosis finds that concerns about the long-term safety of bisphosphonates -- which currently dominate the market -- will help convince primary care physicians and specialists to switch patients to PTH analogues and novel agents such as denosumab. The uptake of denosumab, which has a convenient dosage regimen of bi-annual subcutaneous injections, will drive the agent to achieve blockbuster sales of $2 billion in 2018 for the treatment of osteoporosis and osteopenia. The report also forecasts that Forteo/Forsteo will achieve blockbuster status in 2018 with sales of approximately $2 billion. Forteo/Forsteo's uptake will be achieved as a result of its efficacy in reducing the frequency of fractures as well as the prevalent safety concerns about the bisphosphonates.

The report also finds that that the launches of third-generation selective estrogen receptor modulators (SERMs), most notably Eli Lilly's arzoxifene, will drive market growth. Physicians will increasingly prescribe these agents, particularly if they demonstrate significant efficacy in reducing nonvertebral fractures.

"Interviewed experts indicate that arzoxifene is the most promising of the third-generation SERMs, as they believe it may be as efficacious as Pfizer's Fablyn without increasing mortality," said Decision Resources Analyst Jeremy Goldman, M.D. "If Phase III clinical trial data confirms this, we forecast that arzoxifene will become the market-leading SERM, generating sales of $600 million in 2018."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                     Decision Resources, Inc.
    Christopher Comfort                    Elizabeth Marshall
    781-296-2597                           781-296-2563
    ccomfort@dresources.com                emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Virus Could Help Drive Obesity
2. Back to School Means Return of School Blood Drives
3. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
4. End-to-End HR Performance Benchmarks: Metrics That Will Help Turn the HR Cost Center into a Productivity Driver
5. Customized virus kills brain tumor stem cells that drive lethal cancer
6. National Survey Shows Employee Fears About Consumer-Driven Health Plans on Decline
7. Cancer stem cell subpopulation drives metastasis of human pancreatic cancer
8. Brain Defect Helps Drive Fragile X Syndrome
9. Moffitt Selects Microsofts Azyxxi to Help Drive Personalized Cancer Treatment
10. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
11. Disabilities Rising Among Workers; Need for Employer-Driven Disability Awareness, Support Efforts Also Increases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... ... California, will be included in the 2016 “Guide to America’s Top Plastic Surgeons” ... on the amalgamation of their education, experience, and professional associations. , One ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... veterinarian diagnostic imaging systems and the first company to offer robotic ... a Heart at their tradeshow booth # 941 for the American Association of ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... journeys, announced today that it has raised $6.0 million in an initial round ... Clarify Health’s conviction that patients and their caregivers can receive far better care ...
(Date:11/30/2016)... ... November 30, 2016 , ... The ... been designated as a Cigna Infertility Center of Excellence. The Cigna Center of ... , “It’s an honor to be designated a Cigna Infertility Center of Excellence," ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... health treatment has announced the opening of a new residential mental health treatment ... with mental health issues such as severe anxiety, depression, bi-polar disorder, and other ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 2, 2016 The U.S. ... for Jardiance (empagliflozin) to reduce the risk of cardiovascular ... and cardiovascular disease. "Cardiovascular disease is ... 2 diabetes mellitus," said Jean-Marc Guettier , M.D., ... Products in FDA,s Center for Drug Evaluation and Research. ...
(Date:12/2/2016)... December 2, 2016 Persistence Market ... market in its upcoming report titled, "Global Market Study on Cardiac ... CAGR of -1.4% between 2016 and 2024". The global cardiac ... 2015 and this is likely to decline to US$ ... global cardiac pacemaker market is anticipated to exhibit a ...
(Date:12/2/2016)... 2016 According to the latest market ... on Automated Endoscope Reprocessors: Single Basin Automated Endoscope Reprocessors Product ... 2016 and 2024 " the global automated endoscope reprocessors market was valued at ... at a CAGR of 7.2% during an eight-year forecast period ... by 2024. ...
Breaking Medicine Technology: